Answers are grounded in this paper and cite their sources.
Objective: This study aims to compare all-cause mortality and other hospital outcomes of hospitalized coronavirus disease of 2019 patients using corticosteroids. Materials and methods: A comparative cross-sectional study was performed over three months by collecting data from patients’ medical charts. Results: The sample included 129 patients with type 2 diabetes (T2D) and 293 patients without diabetes, with more men than women in both groups. Patients with T2D were older, namely, those aged more than 70 years (54.3%) with the majority having abnormal glucose levels on admission (76.1%) and at discharge (76.9%). As a primary outcome, higher all-cause mortality was reported among patients without diabetes having more than two comorbidities (38.2%) compared to those with two or single comorbidities (21.0% and 13.9% respectively; p = 0.009). It significantly increased if patients without diabetes had abnormal glucose levels at admission (51.7%; p < 0.001) and discharge (44.7%; p < 0.001) compared to those with normal levels. Critical cases had higher all-cause mortality compared to less severe cases in patients with T2D (58.8%; p < 0.001) and without diabetes (61.0%; p < 0.001). Among secondary outcomes, a higher length of stay in the hospital was noted among patients with T2D (8.4 vs. 7.3 days; p = 0.015), in addition to a significantly higher number of ventilator-free days (2.7 vs. 1.6 days; p = 0.039). Conclusions: Although the treatment with corticosteroids was comparable between patients with and without T2D, hospital outcomes varied between the groups. Findings from this study can help provide additional clinical support for patients with T2D to allow better in-hospital management of COVID-19 cases.
No takes yet. Share an insight, caveat, or question.
Awada et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: